Menu
Back to Journals » Biologics: Targets and Therapy » Volume 10
Update on sepsis-associated acute kidney injury: emerging targeted therapies
Authors Doyle JF, Forni LG
Received 14 February 2016
Accepted for publication 29 March 2016
Published 7 November 2016 Volume 2016:10 Pages 149—156
DOI https://doi.org/10.2147/BTT.S87385
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Doris Benbrook
James F Doyle,1 Lui G Forni1,2
1Department of Intensive Care, Medicine and Surrey Peri-Operative Anaesthesia and Critical Care Collaborative Research Group, Royal Surrey County Hospital NHS Foundation Trust, 2Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK
Abstract: Sepsis-associated acute kidney injury (SA-AKI) is an independent predictor of increased mortality and morbidity. It is essential that further advances in the treatment of sepsis should prioritize targeted therapies in SA-AKI in order to improve these bleak outcomes. As yet, a unique therapy that effectively reduces the impact of acute kidney injury has not been demonstrated. However, the emergence of novel targeted therapies, perhaps in combination, has the possibility of significantly reducing the long-term sequelae of an episode of SA-AKI. In this review, we will focus on the shared etiology of these conditions and how this is managed with targeted therapy and finally the emerging novel therapies that may play an additional role to current treatment strategies.
Keywords: sepsis, acute kidney injury, novel targeted therapy outcome
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.